NCT01265901 2017-10-12IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell CarcinomaImmatics Biotechnologies GmbHPhase 3 Completed339 enrolled
NCT01368276 2015-12-18An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in MelanomaBioVex LimitedPhase 3 Completed31 enrolled 11 charts
NCT01403285 2014-05-19Peptide-based Glioma Vaccine IMA950 in Patients With GlioblastomaImmatics Biotechnologies GmbHPhase 1 Terminated6 enrolled